Targeted photodynamic therapy of breast cancer cells using antibody–phthalocyanine–gold nanoparticle conjugates by Stuchinskaya, T et al.
This article is published as part of a themed issue of 
Photochemical & Photobiological Sciences on 
 
Drug delivery technologies and immunological aspects of 
photodynamic therapy 
Guest edited by Kristian Berg, Jakub Golab, Mladen Korbelik 
and David Russell 
Published in issue 5, 2011 
 
Perspectives 
Photodynamic therapy enhancement of anti-
tumor immunity 
C. M. Brackett and S. O. Gollnick, Photochem. 
Photobiol. Sci., 2011, 10, 649 
PDT-induced inflammatory and host 
responses 
M. Firczuk, D. Nowis and J. Gołąb, Photochem. 
Photobiol. Sci., 2011, 10, 653 
Cancer vaccines generated by photodynamic 
therapy 
M. Korbelik, Photochem. Photobiol. Sci., 2011, 10, 
664 
DAMPs and PDT-mediated photo-oxidative 
stress: exploring the unknown 
A. D. Garg, D. V. Krysko, P. Vandenabeele and P. 
Agostinis, Photochem. Photobiol. Sci., 2011, 10, 
670 
Antitumor immunity promoted by vascular 
occluding therapy: lessons from vascular-
targeted photodynamic therapy (VTP) 
D. Preise, A. Scherz and Y. Salomon, Photochem. 
Photobiol. Sci., 2011, 10, 681 
On the cutting edge: protease-sensitive 
prodrugs for the delivery of photoactive 
compounds 
D. Gabriel, M. F. Zuluaga and N. Lange, 
Photochem. Photobiol. Sci., 2011, 10, 689 
Combination of photodynamic therapy and 
immunomodulation for skin diseases—update 
of clinical aspects 
X.-L. Wang, H.-W. Wang, K.-H. Yuan, F.-L. Li and 
Z. Huang, Photochem. Photobiol. Sci., 2011, 10, 
704 
Nanoparticles: their potential use in 
antibacterial photodynamic therapy 
S. Perni, P. Prokopovich, J. Pratten, I. P. Parkin 
and M. Wilson, Photochem. Photobiol. Sci., 2011, 
10, 712 
Photosensitiser–antibody conjugates for 
photodynamic therapy 
A. J. Bullous, C. M. A. Alonso and R. W. Boyle, 
Photochem. Photobiol. Sci., 2011, 10, 721 
The immunosuppressive side of PDT 
P. Mroz and M. R. Hamblin, Photochem. 
Photobiol. Sci., 2011, 10, 751 
Synthetic approaches for the conjugation of 
porphyrins and related macrocycles to 
peptides and proteins 
F. Giuntini, C. M. A. Alonso and R. W. Boyle, 
Photochem. Photobiol. Sci., 2011, 10, 792 
Combination approaches to potentiate 
immune response after photodynamic therapy 
for cancer 
T. G. St. Denis, K. Aziz, A. A. Waheed, Y.-Y. 
Huang, S. K. Sharma, P. Mroz and M. R. Hamblin, 
Photochem. Photobiol. Sci., 2011, 10, 802 
Clinical and immunolgical response to 
photodynamic therapy in the treatment of 
vulval intrepithelial neoplasia 
S. Daayana, U. Winters, P. L. Stern and H. C. 
Kitchener, Photochem. Photobiol. Sci., 2011, 10, 
810 
Papers 
Cytosolic delivery of LDL nanoparticle cargo 
using photochemical internalization 
H. Jin, J. F. Lovell, J. Chen, K. Ng, W. Cao, L. 
Ding, Z. Zhang and G. Zheng, Photochem. 
Photobiol. Sci., 2011, 10, 817 
Preliminary safety and efficacy results of laser 
immunotherapy for the treatment of metastatic 
breast cancer patients 
X. Li, G. L. Ferrel, M. C. Guerra, T. Hode, J. A. 
Lunn, O. Adalsteinsson, R. E. Nordquist, H. Liu 
and W. R. Chen, Photochem. Photobiol. Sci., 
2011, 10, 822 
Targeted photodynamic therapy of breast 
cancer cells using antibody–phthalocyanine–
gold nanoparticle conjugates 
T. Stuchinskaya, M. Moreno, M. J. Cook, D. R. 
Edwards and D. A. Russell, Photochem. 
Photobiol. Sci., 2011, 10, 832 
Methylene blue covalently loaded 
polyacrylamide nanoparticles for enhanced 
tumor-targeted photodynamic therapy 
M. Qin, H. J. Hah, G. Kim, G. Nie, Y.-E. Koo Lee 
and R. Kopelman, Photochem. Photobiol. Sci., 
2011, 10, 842 
Quantum dot–folic acid conjugates as 
potential photosensitizers in photodynamic 
therapy of cancer 
V. Morosini, T. Bastogne, C. Frochot, R. 
Schneider, A. François, F. Guillemin and M. 
Barberi-Heyob, Photochem. Photobiol. Sci., 2011, 
10, 852 
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f E
as
t A
ng
lia
 L
ib
ra
ry
 o
n 
29
 S
ep
te
m
be
r 2
01
1
Pu
bl
ish
ed
 o
n 
01
 A
pr
il 
20
11
 o
n 
ht
tp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C1
PP
050
14A
View Online
Photochemical &
Photobiological Sciences
Dynamic Article Links
Cite this: Photochem. Photobiol. Sci., 2011, 10, 822
www.rsc.org/pps PAPER
Targeted photodynamic therapy of breast cancer cells using
antibody–phthalocyanine–gold nanoparticle conjugates†
Tanya Stuchinskaya,a Miguel Moreno,a Michael J. Cook,a Dylan R. Edwardsb and David A. Russell*a
Received 11th January 2011, Accepted 7th March 2011
DOI: 10.1039/c1pp05014a
A 4-component antibody–phthalocyanine–polyethylene glycol–gold nanoparticle conjugate is
described for use as a potential drug for targeted photodynamic cancer therapy. Gold nanoparticles
(4 nm) were stabilised with a self-assembled layer of a zinc–phthalocyanine derivative (photosensitiser)
and a heterobifunctional polyethylene glycol. Anti-HER2 monoclonal antibodies were covalently
bound to the nanoparticles via a terminal carboxy moiety on the polyethylene glycol. The nanoparticle
conjugates were stable towards aggregation, and under irradiation with visible red light efﬁciently
produced cytotoxic singlet oxygen. Cellular experiments demonstrated that the nanoparticle conjugates
selectively target breast cancer cells that overexpress the HER2 epidermal growth factor cell surface
receptor, and that they are effective photodynamic therapy agents.
Introduction
There has been a growing interest in the use of gold nanoparticles
in biomedical research due to a combination of unique properties.
Such nanoparticles show good biocompatibility as they are
generally considered to be benign,1 possess a high surface area and
are characterised by facile surface functionalisation through self-
assembly of thiolates on the gold surface via formation of a Au–S
bond.2,3 It has been demonstrated that gold nanoparticles can be
used as efﬁcient drug delivery vehicles both in cancer diagnostics,
e.g., intracellular imaging, and in cancer therapy.1,4
For anti-cancer therapy, molecular recognition towards speciﬁc
cell surface receptors can be achieved by conjugation with an
antibody. A number of studies have shown that gold nanoparticles
conjugated with antibodies are efﬁcient in targeting and then can
destroy cancerous tissue by conversion of near-infrared irradi-
ation into heat.1,5,6 Gold nanostructures, including nanocages,5
nanorods6 and nanoshells,7 have all served as photothermal
therapeutic agents following illuminationwith light ofwavelengths
between 700–800 nm. Typical ‘spherical’ gold nanoparticles of ca.
16 nm have a surface plasmon absorption maximum around 514–
520 nm. However, structural modiﬁcation of the gold nanostruc-
tures during synthesis provides a shift of the absorption band
to the desirable ‘therapeutic window’ of 650–900 nm, i.e., the
near-infrared region where blood and soft tissue are relatively
transparent.5–7 In photothermal experiments, gold nanoparticles
with anti-VEGF antibodies adsorbed on the surface proved to be
aSchool of Chemistry, University of East Anglia, Norwich, Norfolk, NR4
7TJ, UK. E-mail: d.russell@uea.ac.uk
bSchool of Biological Sciences, University of East Anglia, Norwich, Norfolk,
NR4 7TJ, UK
† This article is published as part of a themed issue on immunological
aspects and drug delivery technologies in PDT.
more efﬁcient for the induction of apoptosis in b-chronic lympho-
cytic leukemia cells as compared to gold nanoparticles without
antibodies.8 Disadvantages of photothermal cancer treatment can
be the high power density of irradiation of up to 35 J cm-2 and a
poor selectivity, as both normal and tumour cells can be destroyed
in the path of the laser light.9 However, it has been also reported
that speciﬁcally designed gold nanocages as well as agglomerated
spherical gold nanoparticles can induce cancer cell death at a
power as low as 1.5 J cm-2 using short-pulse irradiation with a
femtosecond laser.5,9
In photodynamic therapy (PDT) of cancer, irradiation with
visible and/or near-infrared light leads to activation of a photo-
sensitiser drug. Upon illumination, the photosensitiser generates
reactive oxygen species, which in turn react rapidly with biological
substrates, initiating an apoptotic or necrotic response and eventu-
ally leading to oxidative damage and cell death.10–12 Since the light
is speciﬁcally chosen to coincide with the maximum absorption
wavelength of the photosensitiser, initial damage following PDT
is limited to the site of concentration of the photosensitiser drug
molecule without destruction of healthy tissue.4
Among some of the promising second-generation photosensi-
tisers are phthalocyanines (Pc), which have a strong absorption
band in the far-red region of the visible spectrum (lmax = ca.
680 nm) and can efﬁciently absorb light (Pc molar extinction
coefﬁcient (e) = ca. 105 M-1 cm-1).11 The efﬁcacy of phthalocyanine
derivatives as a photosensitiser can be signiﬁcantly enhanced
by attachment to the surface of gold nanoparticles. We have
previously shown that the surface-bound Zn(II) phthalocyanine
derivative (C11Pc) exhibits a remarkable enhancement of the
singlet oxygen quantum yield in the presence of an associated
phase transfer reagent, tetraoctylammonium bromide.13,14 This
enhancement in singlet oxygen generation is possibly due to
the phase transfer agent stabilising an active monomeric form
822 | Photochem. Photobiol. Sci., 2011, 10, 822–831 This journal is © The Royal Society of Chemistry and Owner Societies 2011
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of the photosensitiser. Cellular experiments using the HeLa
cervical cancer cell line demonstrated that irradiation of the
conjugates within the cells causes high cell mortality through
the photodynamic effect.13 An extensive photodynamic effect
using the C11Pc nanoparticle conjugates has been demonstrated
recently in vivo where a signiﬁcant decrease in the rate of growth
of a subcutaneously implanted amelanotic melanoma tumour was
observed.15 Similarly, experiments on 5RP7 rat ﬁbroblasts cancer
cells showed promising results in vivo by suppressing the tumour
growth after treatment with zinc phthalocyanine-loaded single-
wall carbon nanohorns.16
Incorporation of cell-targeting peptides or antibodies onto the
nanoparticle surface is highly desirable for therapeutic applica-
tions, as it would enable selective cell and/or nuclear targeting.
Direct physisorption of ﬂuorescently tagged antibodies to the
surface of gold nanoparticles has been used for some time
to produce ‘immunogold’. However, such simple methods of
nanoparticle functionalisation results in poor orientation of the
recognition component (the F(ab)2 region) of the antibody, non-
speciﬁc binding of the nanoparticle conjugates and agglomeration
of small gold nanoparticles.17 These drawbacks can be overcome
by modiﬁcation of the nanoparticle’s surface with polyethylene
glycol (PEG), which has been approved for human intravenous
application and which stabilises the nanoparticles by steric repul-
sion to inhibit colloidal aggregation in physiological conditions.18
The use of a heterobifunctional PEG with two different terminal
moieties allows covalent attachment of an antibody to the outer
end of the polyethylene glycol chain, thus maintaining availability
of antibody binding sites to cell surface receptors. It has been
demonstrated previously that nanoparticles modiﬁed with mixed
receptor-mediated endocytosis peptide andbifunctionalHS-PEG-
COOH 5000 monolayers were efﬁciently internalised by HeLa
cells.19,20
Despite the signiﬁcant efforts to develop modiﬁed nanostruc-
tures for efﬁcient PDT treatment, it still remains a challenge to
develop a nanostructured system based on surface-functionalised
gold nanoparticles that combines molecular recognition with
effective production of reactive singlet oxygen under irradia-
tion. In this study we show that it is possible to combine an
efﬁcient singlet oxygen generating hydrophobic photosensitiser
with cancer-speciﬁc targeting antibodies on the surface of gold
nanoparticles. Importantly, these multifunctional gold nanoparti-
cle conjugates are water-soluble, a characteristic which is essential
for antibody stability and for the facile delivery of conjugates for
photodynamic treatment, but still retain the ability to generate
signiﬁcant levels of singlet oxygen. The preparation and prop-
erties of the 4-component (anti-HER2 antibody–phthalocyanine
photosensitiser–PEG–gold nanoparticle) nanoparticle conjugates
(Fig. 1) are described. Further, it is shown that the nanoparticle
conjugates can be used to speciﬁcally target and then photody-
namically destroy breast cancer cells which overexpress the HER2
cell surface receptor.
Experimental
Materials and methods
All solvents and reagents were reagent-grade and were used as
received. Breast carcinoma cell lines (SK-BR-3 and MDA-MB-
Fig. 1 The complete 4-component system of photosensitiser–nanoparti-
cle conjugates. The conjugates incorporate the photosensitiser (a derivative
of zinc(II) phthalocyanine, C11PC), the heterobifunctional HS-polyethy-
lene glycol-COOH and the HER2 (ErbB2) mouse monoclonal antibody,
all on the gold nanoparticle surface.
231) were obtained from the Cancer Research UK bank. Normal
mammary epithelial cells (MCF-10A) were purchased from the
American Type Cell Culture (ATCC) together with Mammary
Epithelial GrowthMedia. Cell culture growthmedium for the SK-
BR-3 and MDA-MB-231 cell lines was purchased from GIBCO.
Cell-based assays (ApoToxGlo Triplex assay, Caspase-Glo 3/7
and CytoTox-One homogeneous membrane integrity assay) were
purchased from Promega. MTT [(3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] was obtained from Sigma
Aldrich. The monoclonal antibody against ErbB-2 (HER2) was
purchased from Invitrogen.
UV-Visible absorption spectra were recorded on a Hitachi U-
3000 UV-visible spectrophotometer, while ﬂuorescence spectra
were obtained on a Hitachi F-4500 ﬂuorescence spectrometer.
All laser excitation experiments for the cell-based assays were per-
formed using a 632.8 nmHeNe laser (Uniphase 1125P) at a ﬂuence
rate of 34 mW cm-2 and a light dose of 10.2 J cm-2. The particle
size of the antibody–photosensitiser nanoparticle conjugates was
measured on a transmission electron microscope (JEOL JEM-
2000EX). A typical TEM image of the nanoparticle conjugates
is shown in Fig. 2(A). Centrifugation of the nanoparticles was
performed using a Beckman Coulter AllegraTM X-22RCentrifuge.
Elemental analysis of the photosensitiser-bound nanoparti-
cles to determine the number of phthalocyanine molecules per
nanoparticle was achieved using inductively coupled plasma-mass
spectrometry (ICP-MS). The amount of gold and zinc (as amarker
for the phthalocyanine photosensitiser) within the nanoparticle
conjugates was measured on an Agilent 7500ce ICP-MS, ﬁtted
with a concentric Micromist nebuliser and water-cooled Scott
double-pass spray chamber. The standards used for calibration
were from Merck (Merck VI Multi Element Standard) for zinc
and from CPL International (Single Element Gold 1000 ± 3 mg
ml-1) for gold.
Measurements of the cell-based assays were performed on En-
Vision (Wallac) 2103 Multilabel Reader (Perkin Elmer) equipped
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci., 2011, 10, 822–831 | 823
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f E
as
t A
ng
lia
 L
ib
ra
ry
 o
n 
29
 S
ep
te
m
be
r 2
01
1
Pu
bl
ish
ed
 o
n 
01
 A
pr
il 
20
11
 o
n 
ht
tp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C1
PP
050
14A
View Online
Fig. 2 (A) A TEM image of the gold nanoparticles stabilised with the Zn phthalocyanine photosensitiser and the
HS-polyethylene glycol-COOH and with the HER2 antibody conjugated to the PEG (scale bar = 10 nm), (B) structure of
1,1¢,4,4¢,8,8¢,15,15¢,18,18¢,22,22¢-tetradecakisdecyl-25,25¢-(11,11¢dithiodiundecyl) diphthalocyanine zinc (C11Pc).13–15
with an EnVision work station. Luminescence was measured with
a 700 nm low-pass luminescence ﬁlter. Fluorescence wasmeasured
using excitation and emission ﬁlters recommended by the cell-
based assay provider. The absorbance intensity for the colorimetric
MTT assay was measured on a Dynatech MRX plate reader at
550 nm.
The cellular uptake of the nanoparticle conjugates was observed
using a confocal laser scanning microscope (Carl Zeiss, LSM
510 meta). Differential Interference Contrast (DIC) images were
obtained using 633 nm HeNe laser excitation with ﬂuorescence
emission measurement between 650–720 nm. A 63¥, 1.4 NA
objective was used to obtain high-resolution images.
Preparation and characterisation of the 4-component nanoparticle
conjugates [C11Pc–PEG–antibody–gold nanoparticles]
The photosensitiser used in this study was 1,1¢,4,4¢,8,8¢,15,15¢,18,
18¢,22,22¢-tetradecakisdecyl-25,25¢-(11,11¢dithiodiundecyl) diph-
thalocyanine zinc (C11Pc). The structure of this photosensitiser
is shown in Fig. 2(B). This photosensitiser was prepared as
previously reported.13–15 Gold nanoparticles of ca. 4 nm in
diameter were synthesised using the method originally described
by Brust et al.,2 albeit with modiﬁcations. In a typical experiment,
the C11Pc phthalocyanine derivative (8 mg) was dissolved in
tetrahydrofuran (THF) (4 ml). PEG-COOH 3000 Da (a-thio-w-
carboxy polyethylene glycol, 30 mg, Iris Biotech GmbH (3274
Da)) in THF (8 ml) was added, and the mixture was stirred
vigorously for 5 min at room temperature. Gold(III) chloride
tetrahydrate (4.8 mg in 4.8 ml of THF) was added to the
solution with further stirring for 5 min. An aqueous solution of
sodium borohydride (6 mg in 4.8 ml) was added dropwise with
continuous stirring, and the solution was further stirred at room
temperature overnight in the dark. The solvent was removed by
rotary evaporation at 60 ◦C, and the particles were re-suspended in
MES (2-(N-morpholino)ethanesulfonic acid) buffer, pH 5.5 with
0.05% Tween 20 (Polyoxyethylene (20) sorbitan monolaurate, a
non-toxic polysorbate surfactant, obtained from Sigma–Aldrich).
The particles were then centrifuged in polypropylene Eppendorf
tubes (1 ml) at 14 000 rpm for 30 min. The supernatant containing
the particles was removed from the pellet with a micropipette
and then characterised using UV-visible spectrophotometry. For
control experiments, PEGylated gold nanoparticles were also
prepared using the samemethod as described above for theC11Pc–
PEG–gold nanoparticles, but without addition of the C11Pc
phthalocyanine derivative.
Attachment of the monoclonal antibody speciﬁc to the
HER2 receptors was achieved via an amide linkage to
the HS-PEG-COOH 3000. The amide bond was achieved
through EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride, obtained from Sigma–Aldrich) and NHS (D-
hydroxysulfosuccinimide sodium salt, from Fluka) two-step cou-
pling activation of the carboxylic group of the PEG derivative.
The activation converted the carboxylic moiety of the PEG to
a succinimidyl ester, which then reacts with an amine group on
the antibody forming a stable amide bond between the PEG and
the antibodies.21 EDC (0.4 ml) and NHS (1.1 mg) were added
to 1 ml of the photosensitiser–PEG nanoparticle conjugates, the
mixture was stirred for 30 min at room temperature, centrifuged
at 9000 rpm for 30 min in ultra-ﬁltration spin columns, and the
particles were re-suspended in PBS (phosphate saline buffer pH =
7.4, ﬁlter sterilised). Then 1 ml of the HER2 antibody (1 mg
ml-1) was added to 1 ml of the activated nanoparticles, stirred
for 2.5 h, mixed by orbital shaking for 15 h at 1400 rpm, placed
into ultraﬁltration spin columns and then centrifuged at 14 000
rpm for 30 min. The particles were re-suspended in PBS (pH = 7.4,
ﬁlter sterilised, 400 ml per column) and characterised using UV-
visible spectrophotometry. The stock solution of nanoparticles in
PBS was adjusted to a concentration of 5 mM with respect to the
C11PC phthalocyanine derivative, and diluted for the cell line tests
as required.
Measurement of singlet oxygen production
The generation of intracellular reactive oxygen species by the anti-
HER2 antibody phthalocyanine–PEG–gold nanoparticle conju-
gates was determined using the molecular probe disodium, 9,10-
anthracenedipropionic acid (ADPA). Singlet oxygen converts the
ADPA into an endoperoxide which can be monitored by UV-
visible spectrophotometry.22 100 ml of ADPA solution (1.2 mM
in methanol) was added to 900 ml of the nanoparticle conjugates
in a quartz cuvette and stirred thoroughly. UV-visible absorption
spectra were measured in the range 300–800 nm. The solution was
irradiated using the HeNe 632.8 nm laser. During irradiation the
solution was vigorously stirred. The production of singlet oxygen
was determined by the decay of the absorbance intensity of the
ADPA 400 nm absorption band every 5 min for 30 min.
824 | Photochem. Photobiol. Sci., 2011, 10, 822–831 This journal is © The Royal Society of Chemistry and Owner Societies 2011
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Cell culture
Breast carcinoma cell lines (SK-BR-3 and MDA-MB-231) were
routinely cultured in 75 cm3 tissue culture ﬂasks in Dulbecco’s
Modiﬁed Eagle Medium (DMEM) supplemented with 10% fetal
calf serum (FCS) and 1% L-glutamine. Normal mammary epithe-
lial cells (MCF-10A) were cultured in 75 cm3 tissue culture ﬂasks
in ATCC complete growth medium supplemented with 100 ng
ml-1 cholera toxin. The amount of cells for each cell-based assay
and cell viability was monitored by counting viable cells in a
hemocytometer by using the trypan blue exclusion method.23
Analysis of nanoparticle conjugate uptake by confocal microscopy
Cells (25 ¥ 104 cells per well) were seeded onto 6-well plates on
round coverslips (diameter 18 mm) in 2 ml of DMEM growth
medium and left to attach for 24 h. The nanoparticle conjugates
(0.8 mM) were added and the cells were incubated for 3 h. The
cells were rinsed with 2 ml of phosphate-buffered saline (PBS)
3 times. The DMEM medium was replaced with phenol red
free medium, and the cells were mounted on a 37 ◦C heated
stage. The cells were observed using a confocal laser scanning
microscope (Carl Zeiss, LSM 510 meta) using 633 nm HeNe
laser excitationwith ﬂuorescence emissionmeasured between 650–
720 nm. Differential Interference Contrast (DIC) images were
collected simultaneously with transmitted light from the 633 nm
excitation. In order to monitor changes in cell viability, a dead cell
marker, propidium iodide, was used according to the published
protocol.24 Cells were stained with propidium iodide (2 mg ml-1,
from Invitrogen) for 10 min in the dark and then observed with
the confocal microscope combined with DIC using 543 nm HeNe
laser excitationwith ﬂuorescence emissionmeasured between 620–
720nm(excitation/emissionmaximumwavelengths for propidium
iodide are 536 nm/620 nm respectively). Cells incubated in the
absence of nanoparticle conjugates were used as a control. Images
were processed and composite images were obtained using Zeiss
LSM Image Browser Version 4.2.0.121.
Measurement of cell viability, apoptosis and proliferation
Cells were seeded onto 96-well plates, 1 ¥ 104 cells per well in 100 ml
of DMEM supplemented with 10% FCS and 1% L-glutamine
(SK-BR-3 and MDA-MB-231 cell lines) or in ATCC complete
growth medium supplemented with 100 ng ml-1 cholera toxin
(MCF-10A cell line). The cells were counted with a Neubauer
hemocytometer. The 96-well plates were obtained from Fisher
Thermo Scientiﬁc (Nunc) as either clear or solid white styles
depending on assay requirement. Plates were incubated overnight
at 37 ◦C under a 5% CO2 atmosphere. The medium in the wells
was then replaced with fresh medium containing the antibody–
photosensitiser nanoparticle conjugates (ﬁnal concentration was
10 nM of the phthalocyanine photosensitiser assembled on the
gold nanoparticles, ca. 0.03 mg of the nanoparticle conjugates
per 100 ml), and incubation continued for 2 h (unless speciﬁed
otherwise). After incubation, the cells were washed with PBS
buffer 3 times to remove non-bound nanoparticle conjugates, and
the medium was replaced. Each well was then irradiated with the
HeNe 632.8 nm laser for 5 min with a ﬂuence rate of 34 mW cm-2,
light dose 10.2 J cm-2. The intensity of the laser light source was
measured using a power meter (Power Max 500AD Molectron).
MTT assay
The effect of the nanoparticles on cell viability was de-
termined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, Sigma) assay.25,26 Cells at a density
of 1 ¥ 104 cells per well were seeded on clear 96-well plates
and treated with the nanoparticle conjugates as described above,
followed by light irradiation with the HeNe 632.8 nm laser for 5
min. 10 ml of the MTT solution (5 mg ml-1 in PBS) was added
to each well together with 200 ml of DMEM or ATCC growth
medium, depending on the cell line. The plates were further
incubated for 4 h at 37 ◦C. Then the medium was removed and the
resultant formazan crystals were washed with 200 ml PBS (3 times)
and then dissolved in 200 ml of dimethyl sulfoxide. The absorbance
intensity of each well was measured at 550 nm. Each variable
(concentration of nanoparticle conjugates, incubation time and
irradiation time) was assessed through MTT assay in triplicate.
ApoTox-GloTM Triplex Assay
The ApoTox-GloTM triplex assay enables assessment of cell
viability, cytotoxicity and caspase activation events within a
single assay well. The ﬁrst part of the assay simultaneously
measures two protease activities: one is a marker of cell viability
(glycylphenylalanyl-aminoﬂuorocoumarin; GF-AFC), and the
other is a marker of cytotoxicity (bis-alanylalanyl-phenylalanyl-
rhodamine 110; bis-AAF-R110). The live- and dead-cell proteases
produce different products, AFC and R110 respectively, which
have different excitation and emission spectra, allowing them to
be detected simultaneously. The protocol is combined with the
luminescent Caspase-Glo 3/7 assay to monitor cell apoptosis.
The apoptotic response was reﬂected by an increase in caspase-3/7
activity, whereas the cytotoxic responses weremarked by decreases
in AFC (live cell) ﬂuorescence and increases in R110 (dead cell)
ﬂuorescence.27
Cells at a density of 1 ¥ 104 cells per well were seeded
on solid white 96-well plates and treated with nanoparticle
conjugates followed by irradiation as described above. 20 ml of
viability/cytotoxicity reagent containing both GF-AFC substrate
and bis-AAF-R110 substrate was added to all wells, and the
content was mixed by orbital shaking for one minute. The cells
were incubated for 1 h at 37 ◦C, and the two ﬂuorescence
signals were recorded simultaneously. The ﬂuorescence signal to
determine cell viability was recorded with 400Ex/505Em ﬁlters,
and the ﬂuorescence signal monitoring the cell cytotoxicity was
recorded using 485Ex/520Em ﬁlters. After measurement of cell
viability and cytotoxicity, 100 ml of the Caspase-Glo 3/7 assay was
added to all wells, and the luminescence signal from the caspase-
3/7 activation was measured after 30 min of incubation. Each
plate had the cells without any treatment as negative controls.
Staurosporine (10 mM, 1 ml per 100 ml from 1mMstock inDMSO)
was used as an apoptosis positive control. Lysis solution Triton
X 100 (2 ml per 100 ml from 9% stock in DMSO) was used as
a positive control to induce the cell death. Each experiment was
performed in triplicate.
CytoTox-ONETM homogeneous membrane integrity assay
The CytoTox-ONETM Assay is a rapid, ﬂuorescent measure of
the release of lactate dehydrogenase (LDH) from cells with a
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci., 2011, 10, 822–831 | 825
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damaged membrane. LDH released into the culture medium is
measured with a 10-minute coupled enzymatic assay that results
in the conversion of resazurin to resoruﬁn. The reaction can
be performed directly in a homogeneous format in assay wells
containing amixed population of viable and damaged cells.28 Cells
(1 ¥ 104 cells ml-1) were placed in 96-well white plates in 100 ml of
DMEM or ATCC growth medium, depending on the cell line and
incubated with the nanoparticle conjugates as described above.
The plates were equilibrated at room temperature for 30 min.
100 ml of CytoTox-ONETM reagent was added to each well and
the plates were incubated for 10 min at room temperature. The
ﬂuorescence signal monitoring the cell proliferation was recorded
with 560Ex/590Em ﬁlters. Lysis solution (TritonX 100 9%) was used
as a positive control for maximum LDH release. Cytotoxicity was
expressed relative to the basal LDH release from untreated control
cells.
Results and discussion
In order to develop multifunctional gold nanoparticles as a
potential drug delivery system for PDT, a 4-component system
consisting of a phthalocyanine derivative as the photosensitiser
together with a heterobifunctional polyethylene glycol (HS-PEG-
COOH) was self-assembled onto the gold nanoparticle surface.
These functionalised goldnanoparticleswere then conjugatedwith
HER2 monoclonal antibodies. The HER2 antibodies speciﬁcally
bind to HER2 receptors which are over-expressed on the cellular
surface in ca. 25% of all breast cancer cases.29
TheC11Pc phthalocyanine derivative used in this work has been
shown previously to be a hydrophobic and an efﬁcient sensitiser
of singlet oxygen (UD = 0.45).14 To deliver this photosensitiser
for PDT, previously we synthesised gold nanoparticles using
the Brust method2 which incorporated a phase transfer reagent,
tetraoctylammonium bromide, together with the phthalocyanine
as a stabilising self-assembled monolayer.14 These phthalocyanine
nanoparticles were soluble in polar solvents, such as ethanol,
and were shown to be useful PDT agents for the destruction
of HeLa cervical cancer cells.13 In order to develop water-
soluble photosensitiser–gold nanoparticles, we have modiﬁed
the synthetic strategy to incorporate a polyethylene glycol (HS-
PEG-COOH, 3 kDa). This bifunctional PEG contains a thiol
group for self-assembly onto the gold surface and a terminal
carboxy group for coupling of antibodies. Solutions of the
C11Pc phthalocyanine derivative and the HS-PEG-COOH were
combined. Gold nanoparticles were synthesised in this solution
in order to form a mixed self-assembled monolayer surrounding
the particles. The co-assembled species stabilised the ca. 4 nm
gold nanoparticles. The phthalocyanine–PEG–gold nanoparticles
were found to be soluble and stable in aqueous solutions. For
future in vivo studies, an additional advantage of coating gold
nanoparticles with polyethylene glycol is that it has been shown
to increase the blood circulation time of the nanoparticles and
subsequent accumulation within tumours.4
To achieve a targeting capability towards breast cancer cells that
overexpress the HER2 cell surface receptor, the phthalocyanine–
PEG–gold nanoparticles were conjugated with anti-HER2 anti-
bodies. A surfactant, Tween 20 (0.05% in buffer), was initially
added to the phthalocyanine–PEG–gold nanoparticles. This de-
tergent was used to aid the dispersion of the nanoparticles in water
and physiological solutions,30 and is commonly used as a washing
agent in immunoassays (such as Western blots or ELISAs) to
prevent non-speciﬁc antibody binding.31 Additionally, it has also
been shown that a small amount of surfactant can be used to pre-
vent zinc(II) phthalocyanine agglomeration in order to secure high
singlet oxygen production.32 Following the EDC/NHS two-step
antibody coupling chemistry, the resultant anti-HER2 antibody–
phthalocyanine–PEG–gold nanoparticle conjugates were washed
and re-suspended in phosphate-buffered salinewithout any surfac-
tant in order to decrease the risk of cell lysis andmembrane protein
solubilisation during cell treatment.ATEM image of the stabilised
4-component nanoparticle conjugates is shown in Fig. 2(A).
To ensure that high levels of singlet oxygen are produced, it is
important to avoid excessive dimerisation of the phthalocyanine
photosensitiser, since a higher degree of aggregation leads to
a loss of central metal accessibility and, as a result, to a
signiﬁcant decrease of photocatalytic activity.33 The presence of
a monomer–dimer equilibrium of the phthalocyanine derivative
in solutions was observed previously via UV-visible absorption
spectrum as speciﬁc electronic transitions in the Q band (l =
600–800 nm).14,33,34 We have tested the degree of phthalocyanine
derivative agglomeration on the surface of gold nanoparticles
using UV-visible absorption spectrometry at various stages of
the nanoparticle conjugate preparation. Fig. 3 shows a visible
absorption spectrum of the zinc(II) phthalocyanine derivative as
part of the 4-component nanoconjugates. Two strong absorption
bands in the far-red region of the visible spectrum correspond to
monomeric (lmax(monomer) ca. 698 nm) and dimeric (lmax(dimer)
ca. 644 nm) forms of the octyl-substituted zinc(II) phthalocyanine
derivative, respectively.14,34 Comparison of the spectrum of the
same conjugates but prior to antibody attachment (Fig. 3, inset)
Fig. 3 Visible absorption spectrum of the Zn–phthalocyanine photosen-
sitiser together with HS-polyethylene glycol-COOH supported on gold
nanoparticles and conjugated with anti-HER2 antibody; absorption at
698 nm and 644 nm corresponds to monomeric and dimeric form of
the phthalocyanine photosensitiser respectively. Inset: Visible absorption
spectrum of the Zn–phthalocyanine photosensitiser together with the
HS-polyethylene glycol-COOH on the gold nanoparticles without anti-
body attached. The ratio between monomeric and dimeric form of the
phthalocyanine was not affected by antibody attachment, thus preserving
the high rate of reactive singlet oxygen production.
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conﬁrmed that the photosensitiser was successfully attached to
the surface of gold nanoparticles, and that the ratio between
monomeric and dimeric form of the C11Pc derivative was not
affected by antibody attachment. ICP-MS analysis of the gold
nanoparticle conjugates suggests that approximately 10 molecules
of the C11Pc phthalocyanine derivative are attached to each
nanoparticle (assuming that the ligand stabilised gold clusters are
cuboctahedrons and that each nanoparticle consists of 309 gold
atoms2,35,36).
For use in photodynamic therapy, the nanoparticle conjugates
must be capable of producing signiﬁcant levels of cytotoxic singlet
oxygen. The production of singlet oxygen is readily monitored
using the molecular probe disodium 9,10-anthracenedipropionic
acid (ADPA).22 In this present study, ADPA was used as the
molecular probe to conﬁrm the photoactivity of the 4-component
nanoparticle conjugates. Under red light (633 nm) irradiation, the
4-component nanoparticle conjugates generated singlet oxygen,
which converted the ADPA into an endoperoxide. This chemical
change in ADPA can be monitored directly by UV-visible spec-
trophotometry via the characteristic absorption band at 400 nm.
Fig. 4 shows the time-dependent decay of the absorption spectrum
of ADPA following irradiation of the nanoparticle conjugates.
A large decrease in the intensity of the ADPA absorption band
occurs within the ﬁrst 5 min of irradiation (Fig. 4(A)), indicating
the conversion of the ADPA to the endoperoxide and the
presence of a high amount of singlet oxygen. After 30 min of
irradiation, nearly 80% of the ADPA has been converted to the
endoperoxide. To ensure that the decreasing absorbance intensity
of the ADPA was not due to changes of the absorption spectrum
of the C11Pc phthalocyanine photosensitiser, the nanoparticle
conjugates were irradiated without the singlet oxygen probe. Fig.
4(B) shows that the Soret band of the phthalocyanine on the
nanoparticle conjugates exhibits a slight decrease in intensity over
the 30 min irradiation period. The decrease of intensity of the
Soret and the absorption bands at 698 and 645 nm is possibly
due to partial photodecomposition of the phthalocyanine on
formation of the singlet oxygen.34 However, it is apparent that
the decreasing absorption spectrum of the ADPA, seen in Fig.
4(A), is signiﬁcantly larger and is due to the production of singlet
oxygen by the nanoparticle conjugates. To determine whether the
singlet oxygen produced by the nanoparticle conjugates is due to
the presence of the photosensitiser, control particles were prepared
without the C11Pc phthalocyanine derivative – the rates of the
decay of the 400 nm absorption band were then compared (Fig.
4(C)). Monitoring the absorbance at a wavelength of 400 nm for
the nanoparticle conjugates with and without the C11Pc shows
that the photosensitiser is essential for the production of singlet
oxygen.
A comparison of phthalocyanine–PEG nanoparticles with and
without antibody attached was also made. It was determined
that attachment of the anti-HER2 antibody did not affect the
rate of singlet oxygen production. This result is consistent with
the measurements of the amount of photocatalytically active
monomeric form of the Zn(II) phthalocyanine present on the
nanoparticle surface,which remains unchangedwhen compared to
the spectrum of the nanoparticle conjugates prior to the covalent
attachment of the HER2 antibodies (Fig. 3). The presence of
the polyethylene glycol on the gold nanoparticle surface possibly
stabilises an active monomeric form of photosensitiser through
Fig. 4 (A) Time-dependent decay of ADPA absorption spectrum as
a result of photobleaching after irradiation in the presence of the
4-component gold nanoparticle conjugates. (B) Time-dependent decay of
the C11Pc–PEG–gold nanoparticle absorption spectrum after irradiation
(C) Singlet oxygen production as monitored by the photobleaching of
ADPA absorption band at 400 nm after irradiation (HeNe laser, 633 nm)
of the 4-component nanoparticle conjugates antibody–C11Pc–PEG–gold
nanoparticles (dots) and antibody–PEG–nanoparticles (with no C11Pc)
(squares, control).
steric repulsion, thus preserving an efﬁcient rate of singlet oxygen
production even without addition of a surfactant.
To determine the suitability of the 4-component nanoparticle
conjugates for PDT, in vitro studies using a breast cancer cell
line that overexpress the HER2 epidermal growth factor receptors
on the cellular surface (SK-BR-3) and a breast cancer cell line
without the receptor overexpression (MDA-MB-231) were per-
formed. Since the phthalocyanine derivative on the nanoparticle
conjugates is ﬂuorescent,13 it is possible to visualise the cellular
uptake and distribution of the nanoparticle conjugates within the
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci., 2011, 10, 822–831 | 827
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Fig. 5 Combined confocal ﬂuorescence and DIC images of non-treated cells (A, SK-BR-3 cell line) and cells after incubation with the 4-component
gold nanoparticle conjugates, [C11Pc] = 0.4 mM: (B, SK-BR-3 cell line) and (C, MDA-MB-231 cell line). The presence of the nanoparticle conjugates
within the cells can be readily seen from the red ﬂuorescence emission following laser excitation at 633 nm. Scale bars are 5 mm in all images.
cancer cells using confocal ﬂuorescence microscopy. Considering
the small size and near-spherical shape of the nanoparticles (prop-
erties that have reported to be favourable for cellular uptake37), it
was envisaged that the cells would internalise the nanoparticle
conjugates through endocytotic processes from the extracellular
environment. Confocalmicroscopy images (Fig. 5) show thatwhen
the nanoparticle conjugates were incubated with the cancer cells
for 3 h, they are taken up, thus delivering the phthalocyanine
photosensitiser directly into the cell interior. In comparison to
untreated cells (Fig. 5(A)), the nanoparticle conjugates can be
readily seen from the red ﬂuorescence emission following laser
excitation at 633 nm for the SK-BR-3 and MDA-MB-231 cell
lines (Fig. 5(B) and (C) respectively). The images demonstrate a
high level of cellular uptake of the nanoparticle conjugates by the
breast cancer cell lines; following irradiation with the red light,
morphological changes to the cellular structure were indicative of
cell mortality.
Further evidence of increased cell mortality following photo-
dynamic treatment with the nanoparticle conjugates was provided
through a series of cell-based assays in vitro. The colorimetricMTT
metabolic activity assay adapted to incorporate a cell irradiation
protocol25,26 was used to determine cell viability. The SK-BR-
3 cell line (cells with HER2 receptors) was used as a target
cell line and contrasted with the MDA-MB-231 breast cancer
cell line that does not over-express HER2 and with normal
(healthy) mammary epithelial cells MCF-10A. The 4-component
nanoparticle conjugates were added to each of the three cell lines
and incubated for 2 h. The amount of nanoparticle conjugates
was about 0.4 ng in 1 ml of phosphate-buffered saline, equivalent
to 10 nM of the monomeric form of C11Pc in each well. After
incubation, cellswerewashed thoroughlywith buffer to remove the
nanoparticle conjugates that had not been internalised, and then
each well was irradiated with a red light (633 nmHeNe laser, total
irradiation dose 10.2 J cm-2). The cells were incubated for a further
18 h before proceeding with the MTT assay. Fig. 6 (A) shows the
results of theMTTassay; the cell viability decreases after treatment
with the nanoparticle conjugates and laser irradiation. The loss
of the cell viability is signiﬁcantly higher for the SK-BR-3 cell
line than that for the cells without HER2 receptor ampliﬁcation.
For the SK-BR-3 cell line, the cell viability decreased by 60%
after treatment with the 4-component nanoparticle conjugates as
compared to non-treated control cells. The breast cancer MDA-
MB-231 cell line exhibited a 25% loss of viability while the
normal mammary epithelial cells MCF-10A only showed a 7%
loss of viability. Cells without nanoparticle conjugate treatment,
or treated with nanoparticles that did not have the photosensitiser
attached, displayed only a limited decrease in viability following
the same treatment regime. An assessment of the damage to
the cellular membrane following photodynamic treatment with
the 4-component nanoparticle conjugates for all three cell lines
was performed using the CytoTox-OneTM homogeneous mem-
brane integrity assay. This assay is a ﬂuorescent measure of
the release of lactate dehydrogenase (LDH) from cells with a
damaged membrane.28 Similar to the cell viability results using
the MTT metabolic activity assay, membrane permeability was
not compromised in normal mammary epithelial cells MCF-10A.
However, the highest level of membrane damage was observed for
the SK-BR-3 cell line with HER2 ampliﬁcation following PDT
treatment with the 4-component nanoparticle conjugates. These
results strongly suggest that the anti-HER2 antibody-conjugated
nanoparticles bind speciﬁcally to the cells that overexpress the
HER2 receptor, thereby enabling targeted destruction of these
breast cancer cells.
In a further assessment of cellular damage, propidium iodide
(PI) was used as a molecular probe for the direct observation with
confocal ﬂuorescent microscopy of cell damage following PDT
treatment. Propidium iodide intercalates with double-stranded
nucleic acids; it is excluded by viable cells but can penetrate
cell membranes of dying or dead cells.24 It was observed that
after treatmentwith the 4-component nanoparticle conjugates and
exposure to red laser light at 633 nm for 10–15 min the SK-BR-
3 breast cancer cells dramatically change morphology, with the
membrane damage as shown for the PI stained cells (Fig. 6(B)).
Further detailed investigation of the cells showed that chromatin
fragments had formed within the SK-BR-3 cells (Fig. 6(B) insert).
Such fragments are indicative of signiﬁcant membrane damage,
as shown by propidium iodide penetration and binding to nucleic
acids inside the cell.
Finally, a further assay, the ApoTox-GloTM Triplex Assay was
used to assess cell viability, cytotoxicity and caspase activation
events within a single assay well.27 Fig. 7 shows the differing
response to PDT treatment for the cell lines with and without
HER2 ampliﬁcation. The ﬁrst part of the assay simultaneously
measures two protease activities, one is a marker of cell viability,
and the other is a marker of cytotoxicity. The live- and dead-cell
proteases produce different products; one is amarker of cell viabil-
ity (glycylphenylalanyl-aminoﬂuorocoumarin; GF-AFC), and the
other is a marker of cytotoxicity (bis-alanylalanyl-phenylalanyl-
rhodamine 110; bis-AAF-R110). AFC and R110 have different
excitation and emission spectra, allowing them to be detected
828 | Photochem. Photobiol. Sci., 2011, 10, 822–831 This journal is © The Royal Society of Chemistry and Owner Societies 2011
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Fig. 6 (A) Viability (MTT assay) of the three different cell lines SK-BR-3,
MDA-MB-231 and MCF-10A, represented as percentage of viable cells
after 3 h treatment with nanoparticle conjugates (10 nM) and illumination
at 633 nm (HeNe laser, dose 10.2 J cm-2). Viability of the breast cancer
cell line SK-BR-3 with HER2 ampliﬁcation signiﬁcantly decreased after
treatment with the 4-component nanoparticle conjugates and irradiation
as compared to the breast cancer cells without HER2 ampliﬁcation
(MDA-MB-231) and normal mammary epithelial cells (MCF-10A).
Each experiment was performed in triplicate, and each experiment was
performed on 3 separate occasions. Error bars represent the relative
standard error. (B) Confocal microscopy/DIC image of SK-BR-3 cell
line after treatment with the nanoparticle conjugates and illumination
following propidium iodide staining. Inset: Propidium iodide penetrates
cellmembranes of dying or dead cells and intercalates into double-stranded
nucleic acids; formation of chromatin fragments was observed.
simultaneously.27 The results demonstrated that the level of cytoxi-
city rises signiﬁcantly for SK-BR-3 on the ﬁrst day following PDT
treatment with the 4-component nanoparticle conjugates, with
a complementary decrease in cell viability compared to controls
(non-treated cells) (Fig. 7 (A) and (B) respectively). However for
the MDA-MB-231 cells (breast cancer cell line without HER2
ampliﬁcation), only a moderate rise of cytotoxicity was observed
when the cells were treated under the same conditions (Fig. 7(A)
and Fig. 7(B)).
Fig. 7 Response to PDT treatment for the breast cancer cell lines
with (SK-BR-3) and without (MDA-MB-231) HER2 ampliﬁcation: (A)
increase in cytotoxicity, (B) decrease in cell viability, (C) increase in
apoptosis as a function of time after treatment of the SK-BR-3 and
MDA-MB-231 cell lines with the 4-component nanoparticle conjugates
(10 nM) and illumination at 633 nm (HeNe laser, 10.2 J cm-2). Data from
the ApoTox-GloTM Triplex Assay, represented in relative ﬂuorescent units
(RFU) or relative luminescent units (RLU) normalised to the ﬂuorescence
or luminescence signal of non-treated cells with background signal from
growth media subtracted. Each experiment was performed in triplicate,
and each experiment was performed on 3 separate occasions. Error bars
represent the relative standard error.
Measurement of cell viability and cytotoxicity in the triplex
assay is combined with the bioluminescent detection of caspase-
3/7 tomonitor cell apoptosis. The apoptotic responsewas reﬂected
by an increase in caspase-3/7 activity at different incubation
times after the cell lines were treated with the nanoparticle
conjugates followed by irradiation (Fig. 7(C)). The apoptotic
response increased sharply for the SK-BR-3 cell line on the
ﬁrst and second day after PDT treatment, as indicated by the
increasing luminescence signal of the assay. In contrast, for the
MDA-MB-231 cell line without HER2 ampliﬁcation, only a low
level of apoptosis was detected following the same time periods
and conditions of red light illumination.
It is known that the singlet oxygen species lifetime is limited
(less than 3.5 ms) and that this cytotoxic species can diffuse only
0.01 to 0.02 mm, which means that the photodamage is limited
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci., 2011, 10, 822–831 | 829
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to the site of concentration of the photosensitiser.38 Depending
on the drug localisation within the cell, the cell death mechanism
may be different. Generally, localisation of the photosensitiser to
the mitochondria or the endoplasmic reticulum causes apoptosis;
however, if the apoptotic route is blocked, the damaged cell will
still die using the autophagic or necrotic pathways.39,40 Primary
photo-damage sites for cells treated with Zn(II) phthalocyanine
have been shown to be theGolgi apparatus with cell necrosis as the
prevailing mode of cell death; mitochondrial localisation of Zn(II)
phthalocyanine was detected only after prolonged incubation
of cells with the drug, promoting cell death via an apoptotic
pathway.41 In our study we observed a signiﬁcant increase in
apoptosis for the SK-BR-3 cell line after treatment with the 4-
component nanoparticles conjugated with the HER2 antibody
(Fig. 7 (C)). The high level of apoptosis suggests a much higher
afﬁnity of the nanoparticle conjugates towards the SK-BR-3
cell line due to the overexpressed HER2. Fast delivery of the
photosensitiser to the intracellular environment possibly promotes
mitochondrial localisation, so that the cells die largely via the
apoptotic pathway. Further study of the sub-cellular localisation
of the 4-component gold nanoparticle conjugates is required to
establish a correlation between the mechanism of cell death and
the primary sites of photo-damage.
Conclusions
In summary, we have developed a 4-component nanoparticle
conjugate which is capable of speciﬁcally targeting and then
photodynamically treating cancer cells. To achieve the speciﬁcity,
we have combined both a phthalocyanine photosensitiser drug
and a primary antibody, speciﬁc to cell surface receptors, on a gold
nanoparticle. Attachment of the anti-HER2 antibodies to the gold
nanoparticle conjugates leads to enhanced drug targeting of breast
cancer cells that overexpress the HER2 receptor on the cellular
surface. Results from several in vitro cell-based assays suggests
that the targeting capability of the 4-component nanoparticle
conjugates enhances the efﬁcacy of PDT cell death when tumour-
associated antigens are present on the cytoplasmic membrane
of the malignant cells. These ﬁrst results of the treatment of
breast cancer cells are very promising, and demonstrate that the
4-component nanoparticle conjugates have a great potential for
targeted photodynamic therapy.
Acknowledgements
Financial support from the Big C Cancer Charity (Grant Number
08-05R) is gratefully acknowledged. The assistance of Dr Paul
Thomas and Robert Posey with the confocal ﬂuorescence mi-
croscopy and the ICP-MS analysis respectively is also gratefully
acknowledged.
References
1 P. Chen, S. Mwakwari and A. Oyelere, Gold nanoparticles: From
nanomedicine to nanosensing, Nanotechnology, 2008, 1, 45–66.
2 M. Brust, M. Walker, D. Bethell, D. J. Schiffrin and R. Whyman,
Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid–
liquid system, J. Chem. Soc., Chem. Commun., 1994, 801–802.
3 C. J. Ackerson, P. D. Jadzinsky and R. D. Kornberg, Thiolate ligands
for synthesis of water-soluble gold clusters, J. Am. Chem. Soc., 2005,
127, 6550–6551.
4 D. K. Chatterjee, L. S. Fong and Y. Zhang, Nanoparticles in photody-
namic therapy: An emerging paradigm, Adv. Drug Delivery Rev., 2008,
60, 1627–1637.
5 J. Chen, D. Wang, J. Xi, L. Au, A. Siekkinen, A. Warsen, Z. Y. Li, H.
Zhang, Y. Xia and X. Li, Immuno gold nanocages with tailored optical
properties for targeted photothermal destruction of cancer cells, Nano
Lett., 2007, 7, 1318–1322.
6 X. Huang, I. H. El-Sayed, W. Qian and M. A. El-Sayed, Cancer cell
imaging and photothermal therapy in the near-infrared region by using
gold nanorods, J. Am. Chem. Soc., 2006, 128, 2115–2120.
7 L. R. Hirsch, R. J. Stafford, J. A. Bankson, S. R. Sershen, B. Rivera,
R. E. Price, J. D. Hazle, N. J. Halas and J. L. West, Nanoshell-mediated
near-infrared thermal therapy of tumors under magnetic resonance
guidance, Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 13549–13554.
8 P. Mukherjee, R. Bhattacharya, N. Bone, Y. K. Lee, C. R. Patra,
S. Wang, L. Lu, C. Secreto, P. C. Banerjee, M. J. Yaszemski, N. E.
Kay and D. Mukhopadhyay, Potential therapeutic application of gold
nanoparticles in b-chronic lymphocytic leukemia (BCLL): enhancing
apoptosis, J. Nanobiotechnol., 2007, 5, 4.
9 X. Huang, W. Qian, I. H. El-Sayed and M. A. El-Sayed, The potential
use of the enhanced nonlinear properties of gold nanospheres in
photothermal cancer therapy, Lasers Surg. Med., 2007, 39, 747–
753.
10 R. R. Allison, H. C. Mota, V. S. Bagnato and C. H. Sibata, Bio-
nanotechnology and photodynamic therapy – State of the art review,
Photodiagn. Photodyn. Ther., 2008, 5, 19–28.
11 C. M. Allen, W. M. Sharman and J. E. Van Lier, Current status of
phthalocyanines in the photodynamic therapy of cancer, J. Porphyrins
Phthalocyanines, 2001, 5, 161–169.
12 S. B. Brown, E. A. Brown and I. Walker, The present and future role
of photodynamic therapy in cancer treatment, Lancet Oncol., 2004, 5,
497–508.
13 M. E. Wieder, D. C. Hone, M. J. Cook, M. M. Handsley, J.
Gavrilovic and D. A. Russell, Intracellular photodynamic therapy
with photosensitizer-nanoparticle conjugates: cancer therapy using a
‘Trojan horse’, Photochem. Photobiol. Sci., 2006, 5, 727–734.
14 D. C. Hone, P. I. Walker, R. Evans-Gowing, S. FitzGerald, A. Beeby, I.
Chambrier, M. J. Cook and D. A. Russell, Generation of cytotoxic
singlet oxygen via phthalocyanine-stabilized gold nanoparticles: A
potential delivery vehicle for photodynamic therapy, Langmuir, 2002,
18, 2985–2987.
15 M. Camerin, M. Magaraggia, M. Soncin, G. Jori, M. Moreno, I.
Chambrier, M. J. Cook and D. A. Russell, The in vivo efﬁcacy of
phthalocyanine-nanoparticle conjugates for the photodynamic therapy
of amelanotic melanoma, Eur. J. Cancer, 2010, 46, 1910–1918.
16 M. Zhang, T. Murakami, K. Ajima, K. Tsuchida, A. S. D.
Sandanayaka, O. Ito, S. Iijima and M. Yudasaka, Fabrication of
ZnPc/protein nanohorns for double photodynamic and hyperthermic
cancer phototherapy, Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 14773–
14778.
17 W.Eck,G.Craig,A. Sigdel,G.Ritter, L. J. Old, L. Tang,M.F. Brennan,
P. J. Allen andM.D.Mason, PEGylated gold nanoparticles conjugated
to monoclonal F19 antibodies as targeted labeling agents for human
pancreatic carcinoma tissue, ACS Nano, 2008, 2, 2263–2272.
18 Y. Cheng, A. C. Samia, J. D. Meyers, I. Panagopoulos, B. Fei and C.
Burda, Highly efﬁcient drug delivery with gold nanoparticle vectors for
in vivo photodynamic therapy of cancer, J. Am. Chem. Soc., 2008, 130,
10643–10647.
19 S. Herrwerth, T. Rosendahl, C. Feng, J. Fick, W. Eck, M. Himmelhaus,
R. Dahint and M. Grunze, Covalent coupling of antibodies to self-
assembledmonolayers of carboxy-functionalized poly(ethylene glycol):
Protein resistance and speciﬁc binding of biomolecules, Langmuir,
2003, 19, 1880–1887.
20 Y. Liu, M. K. Shipton, J. Ryan, E. D. Kaufman, S. Franzen and
D. L. Feldheim, Synthesis, stability, and cellular internalization of
gold nanoparticles containing mixed peptide-poly(ethylene glycol)
monolayers, Anal. Chem., 2007, 79, 2221–2229.
21 Z. Grabarek and J. Gergely, Zero-length crosslinking procedure with
the use of active esters, Anal. Biochem., 1990, 185, 131–135.
22 B. A. Lindig, M. A. J. Rodgers and A. P. Schaap, Determination of the
lifetime of singlet oxygen in D2O using 9,10-anthracenedipropionic
acid, a water-soluble probe, J. Am. Chem. Soc., 1980, 102, 5590–
5593.
23 S. Tolnai, A method for viable cell count, Tissue Culture Association
Manual, 1975, 1, 37–38.
830 | Photochem. Photobiol. Sci., 2011, 10, 822–831 This journal is © The Royal Society of Chemistry and Owner Societies 2011
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f E
as
t A
ng
lia
 L
ib
ra
ry
 o
n 
29
 S
ep
te
m
be
r 2
01
1
Pu
bl
ish
ed
 o
n 
01
 A
pr
il 
20
11
 o
n 
ht
tp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C1
PP
050
14A
View Online
24 D. T. Sasaki, S. E. Dumas and E. G. Engleman, Discrimination
of viable and non-viable cells using propidium iodide in two color
immunoﬂuorescence, Cytometry, 1987, 8, 413–420.
25 T.Mosmann,Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays, J. Immunol.
Methods, 1983, 65, 55–63.
26 I. Roy, T. Y. Ohulchanskyy, H. E. Pudavar, E. J. Bergey, A. R.
Oseroff, J. Morgan, T. J. Dougherty and P. N. Prasad, Ceramic-based
nanoparticles entrapping water-insoluble photosensitizing anticancer
drugs: A novel drug-carrier system for photodynamic therapy, J. Am.
Chem. Soc., 2003, 125, 7860–7865.
27 A. L. Niles, R. A. Moravec, P. E. Hesselberth, M. A. Scurria, W. J.
Daily and T. L. Riss, A homogeneous assay to measure live and dead
cells in the same sample by detecting different protease markers, Anal.
Biochem., 2007, 366, 197–206.
28 S. P. M. Crouch, R. Kozlowski, K. J. Slater and J. Fletcher, The
use of ATP bioluminescence as a measure of cell proliferation and
cytotoxicity, J. Immunol. Methods, 1993, 160, 81–88.
29 M. Mano, Vinorelbine in the management of breast cancer: New
perspectives, revived role in the era of targeted therapy, Cancer Treat.
Rev., 2006, 32, 106–118.
30 J. Duy, L. B. Connell, W. Eck, S. D. Collins and R. L. Smith,
Preparation of surfactant-stabilized gold nanoparticle-peptide nucleic
acid conjugates, J. Nanopart. Res., 2010, 12, 2363–2369.
31 J. G. Kenna, G. N. Major and R. S. Williams, Methods for reducing
non-speciﬁc antibodybinding in enzyme-linked immunosorbent assays,
J. Immunol. Methods, 1985, 85, 409–419.
32 N. E. Koval’skaya, N. A. Kuznetsova, O. L. Kaliya, N. S. Gretsova
and I. V. Sokolova, The efﬁciency of the formation of singlet oxygen
by a sensitizer based on zinc phthalocyanine, Journal of Applied
Spectroscopy, 2001, 68, 287–290.
33 V. Iliev, V. Alexiev and L. Bilyarska, Effect of metal phthalocyanine
complex aggregation on the catalytic and photocatalytic oxidation of
sulfur containing compounds, J. Mol. Catal. A: Chem., 1999, 137, 15–
22.
34 M. J. Cook, I. Chambrier, S. J. Cracknell, D. A. Mayes and D. A.
Russell, Octa-alkyl zinc phthalocyanines: potential photosensitizers for
use in the photodynamic therapy of cancer, Photochem. Photobiol.,
1995, 62, 542–545.
35 M. C. Daniel and D. Astruc, Gold nanoparticles: assembly,
supramolecular chemistry, quantum-size-related properties, and appli-
cations toward biology, catalysis, and nanotechnology, Chem. Rev.,
2004, 104, 293–346.
36 G. Schmid, M. Baumle, M. Geerkens, I. Heim, C. Osemann and T.
Sawitowski, Current and future applications of nanoclusters, Chem.
Soc. Rev., 1999, 28, 179–185.
37 B. D. Chithrani, A. A. Ghazani and W. C. Chan, Determining the size
and shape dependence of gold nanoparticle uptake into mammalian
cells, Nano Lett., 2006, 6, 662–668.
38 S. Hatz, J. D. C. Lambert and P. R. Ogilby, Measuring the lifetime
of singlet oxygen in a single cell: Addressing the issue of cell viability,
Photochem. Photobiol. Sci., 2007, 6, 1106–1116.
39 E. Buytaert, M. Dewaele and P. Agostinis, Molecular effectors of
multiple cell death pathways initiated by photodynamic therapy,
Biochim. Biophys. Acta, Rev. Cancer, 2007, 1776, 86–107.
40 N. L. Oleinick and I. Belichenko, The role of apoptosis in response
to photodynamic therapy: What, where, why, and how, Photochem.
Photobiol. Sci., 2002, 1, 1–21.
41 C. Fabris, G. Valduga, G. Miotto, L. Borsetto, G. Jori, S. Garbisa and
E. Reddi, Photosensitization with zinc(II) phthalocyanine as a switch
in the decision between apoptosis and necrosis, Cancer Res., 2001, 61,
7495–7500.
This journal is © The Royal Society of Chemistry and Owner Societies 2011 Photochem. Photobiol. Sci., 2011, 10, 822–831 | 831
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f E
as
t A
ng
lia
 L
ib
ra
ry
 o
n 
29
 S
ep
te
m
be
r 2
01
1
Pu
bl
ish
ed
 o
n 
01
 A
pr
il 
20
11
 o
n 
ht
tp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C1
PP
050
14A
View Online
